Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06262113 · ClinicalTrials.gov registry record · NA
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
A NA study of Neurofibromatosis 1, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 294
- Enrollment target
- 1
- Study location
NCT06262113: Recruiting NA study of Neurofibromatosis 1, sponsored by Massachusetts General Hospital.
NCT06262113 is a NA study of Neurofibromatosis 1 that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 294 participants, below the 1,023-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06262113, a NA study of Neurofibromatosis 1, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 294 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this fully decentralized, randomized controlled trial is to compare the efficacy of two educational interventions for individuals with Neurofibromatosis 1 (NF1). The primary objective of the study is to determine which intervention leads to higher rates of evidenced-based health screenings for NF1 patients in primary care settings. Adults with NF1 and parents/guardians of children with NF1 from across the U.S. who do not go to a specialized NF clinic and who have an upcoming annual wellness visits (e.g. an annual physical, a well-child visit, etc.) scheduled with a primary care provider (PCP) are eligible to enroll in the study. To see if you might be eligible, fill out a prescreening survey here: https://redcap.link/mynfguide
Primary Outcome
Number of AAP and ACMG recommended health screenings received by the person with NF1 at the annual wellness visit with their PCP, as assessed by patient/parent self-report
Conditions Studied
Interventions
- OTHER Letters about NF1 Care (Content Type 1)
- OTHER Letters about NF1 Care (Content Type 2)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT06262113 shows while recruiting
NCT06262113 is an interventional study that assigns participants to a tested intervention. The registered 294 participants enrollment target is mid-sized for trials with a published cap, below the 1,023-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Neurofibromatosis 1 appearing as the primary indexed condition, and to 2 interventions - of which Letters about NF1 Care (Content Type 1) is the first listed.
NCT06262113 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06262113 about?
NCT06262113 is a clinical study titled "A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1". The goal of this fully decentralized, randomized controlled trial is to compare the efficacy of two educational interventions for individuals with Neurofibromatosis 1 (NF1). The primary objective of the study is to determine which intervention leads to higher rates of evidenced-based health screenin...
What is the current status of trial NCT06262113?
This trial is currently recruiting. It is a NA study. The enrollment target is 294 participants. The study started on 2024-12-03. Estimated completion is 2026-08.
What conditions does trial NCT06262113 study?
This clinical trial studies the following conditions: Neurofibromatosis 1.
What interventions are being tested in trial NCT06262113?
The interventions under investigation include: Letters about NF1 Care (Content Type 1) (OTHER), Letters about NF1 Care (Content Type 2) (OTHER).
Who is sponsoring clinical trial NCT06262113?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06262113 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06262113's enrollment target sits among peer trials
294 6th of 24 higher than 19 of 24 other Neurofibromatosis 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurofibromatosis 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
RECRUITING · NA
-
Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
RECRUITING · NA
-
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
ACTIVE NOT RECRUITING · NA
-
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
RECRUITING
-
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RECRUITING · Phase 1
-
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05775159 · 294 participants · Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- NCT06338865 · 294 participants · NA
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
- NCT06395467 · 294 participants · NA
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
- NCT06574009 · 294 participants · Phase 4
Better Options for Chronic Cancer Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI